Compare VLYPO & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
| Metric | VLYPO | ICUCW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 3732 | 18 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
| Metric | VLYPO | ICUCW |
|---|---|---|
| Price | $25.59 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
| Indicator | VLYPO | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 39.35 |
| Support Level | $25.12 | $0.01 |
| Resistance Level | $25.59 | $0.01 |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 53.00 | 70.49 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.